PGEN
Precigen Inc
NASDAQ · Biotechnology
$4.29
+0.05 (+1.18%)
Open$4.28
Previous Close$4.24
Day High$4.46
Day Low$4.28
52W High$5.23
52W Low$1.11
Volume—
Avg Volume3.06M
Market Cap1.52B
P/E Ratio—
EPS$-0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,591.6% upside
Current
$4.29
$4.29
Target
$72.57
$72.57
$43.64
$72.57 avg
$99.14
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 5.20M | 8.00M | 395.97M |
| Net Income | -166,828,240 | -231,028,490 | -29,622,139 |
| Profit Margin | -3,216.2% | -3,055.4% | -7.5% |
| EBITDA | -165,094,500 | -241,329,089 | -51,308,756 |
| Free Cash Flow | — | — | -33,088,570 |
| Rev Growth | -35.0% | -35.0% | +6.2% |
| Debt/Equity | — | — | 1.01 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |